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Abstract: Venous thromboembolism (VTE) is a common complication after acute ischemic 
stroke that can be prevented by the use of anticoagulants. Current guidelines from the American 
College of Chest Physicians recommend that patients with acute ischemic stroke and restricted 
mobility receive prophylactic low-dose unfractionated heparin or a low-molecular-weight 
heparin. Results from clinical studies, most recently from PREVAIL (PREvention of Venous 
Thromboembolism After Acute Ischemic Stroke with LMWH and unfractionated heparin), sug-
gest that the low-molecular-weight heparin, enoxaparin, is preferable to unfractionated heparin 
for VTE prophylaxis in patients with acute ischemic stroke and restricted mobility. This is due 
to a better clinical beneﬁt-to-risk ratio, with the added convenience of once-daily administration. 
In line with ﬁndings from modeling studies and real-world data in acutely ill medical patients, 
recent economic data indicate that the higher drug cost of enoxaparin is offset by the reduction 
in clinical events as compared with the use of unfractionated heparin for the prevention of  VTE 
after acute ischemic stroke, particularly in patients with severe stroke. With national performance 
measures highlighting the need for hospitals to examine their VTE practices, the relative costs 
of different regimens are of particular importance to health care decision-makers. The data 
reviewed here suggest that preferential use of enoxaparin over unfractionated heparin for the 
prevention of VTE after acute ischemic stroke may lead to reduced VTE rates and concomitant 
cost savings in clinical practice.
Keywords: acute ischemic stroke, cost savings, enoxaparin, unfractionated heparin, venous 
thromboembolism
Introduction
Worldwide, stroke is the second leading cause of death1 and its impact is expected to 
increase with the westernization of lifestyles in developing countries. In addition to 
high rates of mortality, stroke is responsible for signiﬁcant long-term morbidity, with 
permanent disability experienced by 15%–30% of stroke patients and 20% of patients 
requiring institutional care at 3 months after onset.2 There is also a considerable health 
care burden associated with long-term morbidity due to stroke, such that the total 
(direct and indirect) costs of stroke were estimated to be $73.9 billion in 2010 in the 
United States alone.2
Approximately 85% of all strokes are ischemic events2,3 that usually occur as 
a result of thrombosis or embolism. Venous thromboembolism (VTE) is also a 
  common, yet highly preventable, complication following stroke.4 To reduce the 
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  incidence of VTE in patients with acute ischemic stroke and 
restricted mobility, guidelines from the American College 
of Chest Physicians recommend prophylaxis with low-dose 
unfractionated heparin or a low-molecular-weight heparin 
(LMWH).5 Although none of the LMWHs is indicated for 
thromboprophylaxis speciﬁcally in patients with acute isch-
emic stroke, these patients are often categorized as medical 
patients with reduced mobility, a group of patients for which 
the LMWHs dalteparin and enoxaparin are indicated for 
thromboprophylaxis.
This review discusses the risk of VTE in stroke patients, 
describes studies evaluating the efﬁcacy and safety of VTE 
prophylaxis after acute ischemic stroke, and details the rela-
tive costs of different thromboprophylaxis regimens, with 
particular emphasis on data from the PREVAIL (PREvention 
of Venous Thromboembolism After Acute Ischemic Stroke 
with LMWH and UFH) study.6–8
Thromboembolic risk in stroke 
patients
Following a ﬁrst stroke, patients are at signiﬁcantly increased 
risk of a further thrombotic event, ie, VTE (deep vein 
thrombosis or pulmonary embolism), recurrent stroke, or 
myocardial infarction. A recent study of 1,150,336 adult 
  hospitalizations with ischemic stroke in the United States using 
data from the Nationwide Inpatient Sample of the Healthcare 
Cost and Utilization Project, demonstrated that although 
inhospital mortality decreased from 1998–1999 to 2006–2007, 
the largest increase in medical complications in these patients 
was observed for deep vein thrombosis (0.46% versus 0.79%) 
and pulmonary embolism (0.11%   versus 0.27%).9 In the 
absence of thromboprophylaxis, 20%–75% of stroke patients 
may develop deep vein thrombosis, with the wide range 
depending on the methods used to detect deep vein   thrombosis 
and the degree of lower limb paralysis.10,11   Pulmonary 
  embolism is fatal in up to half of all cases.12 Indeed,   pulmonary 
embolism is the third most common cause of death in stroke 
patients, after stroke itself and secondary infections, occurring 
in 1%–2% of patients.12 The risk of VTE is highest in the 
14 days after stroke; however, deep vein thrombosis was 
present in 14%–33% of stroke patients in rehabilitation over 
2 weeks after the primary event.12
Stroke patients are at increased risk of VTE as a result 
of their initial stroke and its consequences, such as limb 
paralysis. In line with other acutely ill medical patients, 
stroke patients often have multiple other complications, 
such as advanced age, immobility, obesity, and venous 
insufficiency. Comorbidities that further increase VTE 
risk are also   common, including cancer, heart failure, and 
severe   respiratory disease.13 For example, in the total patient 
  population of a trial of thromboprophylaxis for the   prevention 
of deep vein thrombosis in acute ischemic stroke, 52% of 
patients were aged over 70 years, 18% were obese, and 
9% had varicose veins.14
Preventing VTE after acute  
ischemic stroke: the role of 
antithrombotic agents
Given the high risk and considerable consequences,   prevention 
of VTE is crucially important following a stroke. However, 
it is essential to rule out hemorrhagic stroke and identify 
patients at increased risk of bleeding complications before 
prescribing pharmacological prophylaxis. Current guidelines 
from the American College of Chest Physicians recommend 
that patients with acute ischemic stroke and restricted 
mobility receive prophylactic low-dose subcutaneous 
unfractionated heparin or LMWH (Grade 1A).5 For patients 
who have contraindications to anticoagulants, intermittent 
pneumatic compression devices or elastic stockings are 
recommended (Grade 1B). Guidelines from the American 
Heart Association/American Stroke Association also rec-
ommend subcutaneous administration of anticoagulants in 
immobilized patients with acute ischemic stroke to prevent 
deep vein thrombosis (Class I, level of evidence A).15 These 
guidelines consider aspirin a potential intervention to prevent 
deep vein thrombosis, but note that it is less effective than 
anticoagulants (Class IIA, level of evidence A).15 Recent 
guidelines from the American College of Physicians 
recommend pharmacologic prophylaxis with unfractionated 
heparin or a LMWH, or a related drug for VTE in medical 
patients (including stroke patients) unless the assessed risk 
for bleeding outweighs the likely beneﬁts.16
Unfractionated heparin
Thromboprophylaxis with unfractionated heparin has been 
shown to reduce the incidence of VTE after acute ischemic 
stroke compared with placebo.10,17,18 Sandercock et al17 
reviewed four small trials in stroke patients and reported 
an overall reduction of 84% in VTE events with unfraction-
ated heparin prophylaxis versus placebo or no treatment. 
However, data were inadequate to enable conclusions to be 
drawn on the safety of unfractionated heparin prophylaxis, 
particularly with respect to hemorrhagic transformation and 
bleeding in patients with known intracerebral hemorrhage.17 
Systematic screening for hemorrhagic transformation in 
patients with cerebral infarcts would be able to provide ﬁrm 
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evidence of this complication, but none of the trials   analyzed 
has this as a prespeciﬁed analysis. Also, the included   studies 
were too small to provide ﬁrm conclusions regarding safety.17 
Subsequently, the International Stroke Trial, a large random-
ized study (approximately 20,000 patients), investigated the 
efﬁcacy and safety of unfractionated heparin administered 
at either 5000 IU or 12,500 IU twice daily.18 Taken together, 
unfractionated heparin signiﬁcantly reduced the incidence 
of pulmonary embolism compared with control (0.5% 
versus 0.8%; P , 0.05), but was associated with a sig-
niﬁcant increase in hemorrhagic stroke (1.2% versus 0.4%; 
P , 0.001) and bleeding complications (1.3% versus 0.4%; 
P , 0.001).18
Low-molecular-weight heparins
Outcomes following prophylaxis with LMWHs or danaparoid, 
a heparinoid, were investigated in a meta-analysis of 10 small 
controlled trials (n = 2855).19 LMWHs/danaparoid versus 
control was associated with significant reductions in 
prospectively identiﬁed deep vein thrombosis (odds ratio [OR] 
0.27; 95% conﬁdence interval [CI] 0.08–0.96) and symptom-
atic pulmonary embolism (OR 0.34; 95% CI 0.17–0.69). 
However, significant increases in major extracranial 
hemorrhage were observed with LMWHs (OR 2.17; 95%   
CI 1.10–4.28).
Subsequently, a number of head-to-head studies have 
compared LMWHs with unfractionated heparin for the 
prevention of VTE after stroke.6,14,19,20 In one study, unfrac-
tionated heparin 5000 IU three times daily and the LMWH 
enoxaparin administered at 40 mg once daily were inves-
tigated in 212 patients.14 The main outcome measures of 
symptomatic or asymptomatic deep vein thrombosis detected 
by venography, pulmonary embolism, death from any cause, 
intracranial hemorrhage including hemorrhagic infarction, or 
any other major bleeding occurred in 37.7% of patients in the 
enoxaparin group and 49.1% in the unfractionated heparin 
group (P = 0.127). Bleeding complications were experienced 
by 2.8% of patients in the enoxaparin group and 1.9% in the 
unfractionated heparin group. Of note, numerically fewer 
patients treated with enoxaparin (13.2%) compared with 
unfractionated heparin (18.9%) had evidence of hemorrhagic 
transformation of acute ischemic stroke.
The PROTECT study (Prophylaxis of Thromboembolic 
Events by Certoparin Trial) compared the LMWH certoparin 
(3000 U anti-Xa once daily; n = 272) with unfractionated 
heparin (5000 IU three times daily; n = 273) in the preven-
tion of VTE following stroke.21 The composite primary 
endpoint of proximal symptomatic or asymptomatic deep 
vein   thrombosis detected by ultrasonography, pulmonary 
embolism, or death related to VTE during treatment occurred 
in 7.0% of patients in the certoparin group compared with 
9.7% in the unfractionated heparin group, demonstrating 
that certoparin was as effective as unfractionated heparin 
(P = 0.0011 for noninferiority). Major bleeding occurred in 
1.1% of patients allocated to certoparin and 1.8% of patients 
allocated to unfractionated heparin.
In the PREVAIL (PREvention of Venous Thromboembo-
lism After Acute Ischemic Stroke with LMWH and unfrac-
tionated heparin) study of 1762 patients with acute ischemic 
stroke and restricted mobility, enoxaparin at a dose of 40 mg 
once daily reduced the risk of the composite primary endpoint 
of symptomatic or asymptomatic deep vein thrombosis, 
detected by contrast venography, or symptomatic or fatal 
pulmonary embolism by 43% compared with unfractionated 
heparin 5000 IU twice daily (10% versus 18%, respectively; 
relative risk 0.57; 95% CI 0.44–0.76; P = 0.0001).6 Bleeding 
complications were similar between groups (both 8%). The 
composite of symptomatic intracranial and major extracranial 
hemorrhage was not signiﬁcantly different between enox-
aparin and unfractionated heparin (11/877 [1.2%] versus 
(6/872) [0.7%]; P = 0.23), but there was a slight, clinically 
signiﬁcant, excess in major extracranial hemorrhage alone 
with enoxaparin compared with unfractionated heparin 
(7/877 [0.8%] versus 0/872 [0.0%]; P = 0.015).
In the PREVAIL study, the rate of VTE was higher in 
patients with more severe strokes (National Institutes of Health 
Stroke Scale [NIHSS] scores $14) than less severe strokes 
(NIHSS scores ,14). Prophylaxis with enoxaparin was associ-
ated with a reduced risk of VTE compared with unfractionated 
heparin in both stroke severity groups (Figure 1).6
Further, a post hoc analysis of data from the PREVAIL 
study indicate that enoxaparin prophylaxis confers a reduced 
risk of VTE, as compared with unfractionated heparin, in 
  multiple patient subgroups. This includes several subgroups 
with or without risk factors in addition to stroke, such as 
patients with diabetes, obesity, and advanced age (Figure 1).6,22 
More recently, a subanalysis of PREVAIL has been conducted 
to study the long-term neurological outcomes associated with 
the use of enoxaparin compared with unfractionated   heparin.23 
Similar improvements in NIHSS and modified Rankin 
scale scores were observed in both groups over the 90-day 
follow-up period. The incidence of intracranial hemorrhage 
was similar in the enoxaparin group and the unfractionated 
heparin group (2.3% versus 2.5%, respectively).
Data from PREVAIL, PROTECT, and seven other 
randomized studies were analyzed in a Cochrane review 
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of LMWHs/heparinoid versus unfractionated heparin in 
3137 patients with acute ischemic stroke.20 Allocation to the 
LMWH group was associated with a reduction in deep vein 
thrombosis compared with unfractionated heparin (OR 0.55; 
95% CI 0.44–0.70); however, the authors concluded that 
there were too few data to provide reliable information 
regarding their effects on other important outcomes, includ-
ing death and intracranial hemorrhage.
Other anticoagulant agents
Several other anticoagulant agents have been studied in 
medical patients or are currently being assessed in   randomized 
controlled trials. These include fondaparinux, rivaroxa-
ban, and apixaban. Fondaparinux (2.5 mg once daily, for 
6–14 days) reduced VTE in older acute   medical patients 
compared with placebo, with a relative risk   reduction of 
46.7% (95% CI 7.7–69.3). No concomitant increase in major 
bleeding events, which occurred in 0.2% of patients in both 
groups, was associated with fondaparinux.24 MAGELLAN 
(Multicenter, Randomized, Parallel Group Efﬁcacy and Safety 
Study for the Prevention of Venous Thromboembolism in 
Hospitalized Medically Ill Patients Comparing Rivaroxaban 
With   Enoxaparin) has recently been completed, and ADOPT 
(A Phase III   Randomized, Double-Blind, Parallel-group, 
Multi-center Study of the Safety and Efﬁcacy of Apixaban 
for Prophylaxis of Venous Thromboembolism in Acutely 
Ill Medical Subjects   During and Following Hospitalization) 
is currently underway. These trials are designed to assess 
the use of extended duration   prophylaxis with apixaban and 
  rivaroxaban, for 30 and 35 days, respectively, in comparison 
with enoxaparin   during hospitalization (6–14 days) and 
placebo after hospital discharge. Preliminary results from 
MAGELLAN showed that rivaroxaban 10 mg once daily was 
noninferior to enoxaparin 40 mg once daily for the primary 
endpoint of major VTE (asymptomatic and   symptomatic 
proximal deep vein thrombosis, nonfatal pulmonary   embolism, 
and VTE-related death) at day 10 ± 4 (2.7% versus 2.7%; P for 
noninferiority = 0.0025). For the extended period of rivaroxaban 
(35 ± 4 days) versus placebo, rivaroxaban was superior (4.4% 
versus 5.7%; P = 0.02). Clinically   relevant bleeding rates 
Stroke-prophylaxis
Stroke-prophylaxis
Diabetes
0.59 (0.40−0.87) 0.23
0.93
0.71
0.98
0.37
0.80
0.29
0.39 (0.22−0.68)
0.53 (0.28−1.00)
0.51 (0.35−0.74)
0.57 (0.31−1.07)
0.50 (0.34−0.72)
0.47 (0.27−0.83)
0.56 (0.37−0.84)
0.46 (0.27−0.78)
0.55 (0.35−0.85)
0.50 (0.32−0.79)
0.72 (0.41−1.28)
0.38 (0.22−0.67)
0.52 (0.31−0.89)
0.54 (0.36−0.79)
No diabetes
No obesity
Previous stroke
 No previous stroke
NIHSS score ≥14
NIHSS score <14
Female
Male
Age >75 years
Age 65−75 years
Age <65 years
0.20 .40 .60 .8
OR (95% CI)
11 .21 .6 1.4
Obesity
24−48 h
Favors enoxaparin Favors UFH
OR (95% CI) P for 
interaction
<24 h
Figure 1 Relative risk of venous thromboembolism for enoxaparin compared with UFH in patients with acute ischemic stroke by patient characteristics in the PREvAiL 
(PREvention of venous Thromboembolism After Acute ischemic Stroke with LMWH [low-molecular-weight heparin] and UFH) study.6 
Reproduced from Sherman DG, et al. Lancet. 2007;369:1347–55 © 2007, with permission from Elsevier.
Abbreviations: CI, confidence interval; NIHSS, National Institutes of Health Stroke Scale; OR, odds ratio; UFH, unfractionated heparin.
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were low but signiﬁcantly higher with rivaroxaban across the 
entire study (2.8% versus 1.2%; P , 0.0001 for days 1–10 
and 1.4% versus 0.5%; P , 0.0001 for days 11–35). Subgroup 
analysis conﬁrmed the overall efﬁcacy and bleeding results for 
most clinical groups including patients with acute ischemic 
stroke, although the number of patients with acute ischemic 
stroke was small.25 Furthermore, rivaroxaban, apixaban, and 
the thrombin inhibitor, dabigatran, have been assessed for 
the prevention of stroke and systemic embolism in patients 
with atrial ﬁbrillation.26–28 However, no studies are currently 
underway directly assessing the efﬁcacy of these agents in 
reducing VTE following acute ischemic stroke.
Mechanical prophylaxis
Intermittent pneumatic compression devices or graduated 
compression stockings are recommended as thrombo-
prophylaxis for patients who have contraindications to 
  anticoagulants. The relationship between symptomatic VTE 
and the use of stockings was assessed based on observational 
data from TAIST (the Tinzaparin in Acute Ischemic Stroke 
Trial) which compared the LMWH, tinzaparin, (175 IU/kg or 
100 IU/kg) with aspirin 300 mg.29 Patients wearing bilateral 
graduated compression stockings for 10 days (n = 374) had 
a nonsigniﬁcant one-third reduction in the odds of VTE as 
compared with those who wore no stockings or wore them 
for less than 10 days (OR 0.65; 95% CI 0.26–1.65).
The large CLOTS (Clots in Legs Or sTockings after 
Stroke) trials were designed to investigate further the role of 
mechanical prophylaxis for preventing VTE in patients with 
acute stroke. In CLOTS trial 1 of 2518 immobile patients with 
acute ischemic stroke, symptomatic or asymptomatic proximal 
deep vein thrombosis, detected by ultrasonography, occurred 
in 10.0% of patients allocated to thigh-length graduated com-
pression stockings and in 10.5% allocated to avoid graduated 
compression stockings, resulting in a nonsigniﬁcant absolute 
risk reduction of 0.5% (95% CI −1.9–2.9).30 Skin breaks, 
ulcers, blisters, and skin necrosis were more common in 
patients allocated graduated compression stockings than in 
the control group (5% versus 1%, respectively; OR 4.18; 95% 
CI 2.40–7.27). In CLOTS trial 2 (n = 3114), symptomatic or 
asymptomatic proximal deep vein thrombosis, detected by 
ultrasonography, occurred in 6.3% of patients who received 
thigh-length stockings and 8.8% who received below-knee 
stockings, an odds reduction of 31% (95% CI 9–47; P = 0.008 
for the absolute difference).31 Skin breaks occurred in 3.9% of 
patients who received thigh-length stockings and 2.9% of 
patients who received below-knee stockings (OR 1.38; 95% 
CI 0.93–2.04; P = 0.11). These results are intriguing because 
it seems that thigh-length stockings were ineffective in 
trial 1, but more effective than below-knee stockings in trial 2. 
Further information on the use of mechanical prophylaxis 
will be obtained from the ongoing CLOTS trial 3, which is 
investigating the use of intermittent pneumatic compression 
versus avoidance of intermittent pneumatic compression.
Cost comparisons
Recently, there has been an increased focus on the total cost 
of different medical regimens within hospitals in the United 
States. Such studies take drug-acquisition costs into consid-
eration and also costs for clinical events (Table 1).7,8,32–34 Two 
studies using a cost-effectiveness analysis model based on 
hypothetical cohorts of medically ill patients have investi-
gated the cost-effectiveness of enoxaparin and unfractionated 
heparin.32,33 In a simulated cohort of 10,000 patients using 
a decision-analytic model with parameter estimates derived 
from published clinical trials, expected numbers of deaths 
attributable to VTE or drug complications were 37 with enox-
aparin 40 mg once daily, 53 with unfractionated heparin 5000 
IU twice daily, and 81 with no prophylaxis.32 In 2001, cor-
responding expected costs of prevention, diagnosis, and man-
agement of VTE were $3,502,000 for enoxaparin, $3,772,000 
for unfractionated heparin, and $3,105,000 for no prophy-
laxis. The incremental cost per death averted with enoxaparin 
prophylaxis versus no prophylaxis was $9100. Enoxaparin 
was a dominant strategy over unfractionated heparin by being 
both more effective and less costly.
In a more recent study by Deitelzweig et al,33 a decision-
analytic model, with model parameters derived from pub-
lished clinical trials and other secondary sources, compared 
the long-term clinical effectiveness, safety, and direct medi-
cal costs between hypothetical cohorts of 10,000 medical 
patients receiving enoxaparin 40 mg once daily, unfraction-
ated heparin 5000 IU twice daily, or no prophylaxis. The 
estimated incidence of VTE at 2 years (including recurrent 
VTE) was 6.8% with enoxaparin, 7.9% with unfractionated 
heparin, and 17.9% with no prophylaxis. Two-year mortal-
ity occurred in 15.7% of enoxaparin patients and 16.0% of 
unfractionated heparin patients. The incidence of major 
bleeding was 0.7%, 1.2%, and 0.6% for enoxaparin, unfrac-
tionated heparin, and no prophylaxis, respectively. Total 
average costs per patient were $1264 for enoxaparin, $1585 
for unfractionated heparin, and $2245 for no prophylaxis; 
therefore, enoxaparin was dominant over the two alternative 
strategies. No realistic parameter changes resulted in prophy-
laxis using enoxaparin being more costly than unfractionated 
heparin prophylaxis.
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In a 2006 study, costs were investigated in different 
medical patient groups at risk of VTE who received a LMWH 
or unfractionated heparin based on real-world data from a 
large inpatient database.34 In the 153,552 patients with acute 
ischemic stroke, the mean ± standard deviation total drug 
cost per patient was $803 ± 993 in the LMWH group and 
$617 ± 2701 in the unfractionated heparin group. Importantly, 
the mean total hospital cost per patient was $8608 ± 7190 for 
enoxaparin and $8911 ± 8291 for unfractionated heparin.
Recently, data from PREVAIL were used to investigate 
the economic impact further, from the payer perspective and 
the hospital perspective, of a LMWH versus unfractionated 
heparin speciﬁcally in patients after acute ischemic stroke.7,8 
For the payer perspective, payer costs for clinical events 
were based on the median cost in Centers for Medicare and 
Medicaid Services claim information. The average costs 
of clinical events per patient to the payer were $1758 with 
enoxaparin and $2854 for unfractionated heparin, resulting 
in a net saving of $1096 with enoxaparin.7 The drug costs 
were higher for enoxaparin than unfractionated heparin 
($260 versus $59, respectively); however, when the total cost 
of clinical events and drug costs were considered together, 
enoxaparin was associated with a total cost saving of $895 
per patient compared with unfractionated heparin ($2018 
with enoxaparin versus $2913 with unfractionated heparin). 
In addition to this model scenario that used the VTE deﬁnition 
from the PREVAIL study, which includes symptomatic or 
asymptomatic deep vein thrombosis, symptomatic pulmonary 
embolism, or fatal pulmonary embolism,6 two other model 
scenarios were used to calculate costs in order to account 
for different deﬁnitions of VTE. The second model scenario 
grouped events into two categories, major VTE including 
pulmonary embolism, symptomatic deep vein thrombosis 
and asymptomatic proximal deep vein thrombosis, and minor 
VTE deﬁned as asymptomatic distal deep vein thrombosis 
only. The third model scenario used the European Committee 
for Medicinal Products for Human Use (CHMP) deﬁnition, 
which includes well documented proximal deep vein throm-
bosis, well documented nonfatal pulmonary embolism, and 
death from all causes including pulmonary embolism. Only 
the deﬁnition of efﬁcacy endpoints changed between the three 
scenarios and the deﬁnition of bleeding was consistent across 
all models, and included intracranial hemorrhage, major 
extracranial hemorrhage, and minor hemorrhage for all three 
model scenarios.7 Despite higher drug costs for enoxaparin 
compared with unfractionated heparin, total cost per patient 
remained lower for enoxaparin in all three scenarios. Savings 
ranged from $517 per patient in the CHMP scenario to $895 
per patient in the PREVAIL scenario. In patients with more 
severe strokes (NIHSS scores $14), the use of enoxaparin 
Table 1 Cost comparison studies for use of unfractionated heparin versus enoxaparin for thromboprophylaxis
Reference Patient  
population
Parameter estimates Cost estimate Drug acquisition cost, $ Total cost, $
UFH Enoxaparin UFH Enoxaparin
McGarry  
et al32
Medical patients Decision-analytic model  
based on a hypothetical  
cohort (n = 10,000);  
model parameters based  
on clinical trials and other  
secondary sources
Cost per patient  
(30 days)
112 172 3772 3502
Deitelzweig  
et al33
Medical patients Decision-analytic model  
based on a hypothetical  
cohort (n = 10,000);  
model parameters based  
on clinical trials and other  
secondary sources
Cost per patient  
(2 years)
68 211 1585 1264
Burleigh  
et al34
Acute ischemic  
stroke  
subpopulation
Real-world data from  
a large inpatient database  
(n = 153,552 ischemic  
stroke patients)
Hospital cost  
per patient
617 803 8911 8608
Pineo et al7 Acute ischemic  
stroke
Decision-analytic model  
based on PREvAiL  
clinical trial
Payer cost per  
patient
59 260 2913 2018
Pineo et al8 Acute ischemic  
stroke
Decision-analytic model  
based on PREvAiL  
clinical trial
Hospital cost  
per patient
259 360 922 782
Abbreviations:  PREvAiL,  PREvention  of  venous  Thromboembolism  After  Acute  ischemic  Stroke  with  LMWH  [low-molecular-weight  heparin]  and  UFH;   
UFH, unfractionated heparin.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
104
Pineo et alClinicoEconomics and Outcomes Research 2012:4
over unfractionated heparin resulted in even greater total 
cost-savings ($1800 per patient) than in patients with less 
severe stroke (NIHSS scores ,14; $488 per patient).
In a similar analysis, costs for hospitals were evaluated 
rather than costs to the payer. The costs of clinical events 
for hospitals were based on mean hospital costs in the 
  Premier Perspective™ multihospital database, which is one 
of the largest United States hospital clinical and economic 
databases. This database contains detailed United States 
inpatient care records from over 600 hospitals of principal 
and secondary diagnoses, inpatient procedures,   administered 
laboratory tests, dispensed drugs, and demographic 
information. The average cost to the hospital, when taking 
into account the costs of VTE and bleeding, was similarly 
lower with enoxaparin than with unfractionated heparin 
($422 versus $662, respectively), with a net saving of $240 
per patient if enoxaparin was used.8 The drug costs, including 
drug administration costs, were higher for enoxaparin than 
unfractionated heparin ($360 versus $259, respectively); 
however, when the total cost of clinical events and drug costs 
were considered together, enoxaparin was associated with a 
total cost saving of $140 per patient compared with unfrac-
tionated heparin ($782 with enoxaparin versus $922 with 
unfractionated heparin). Again, the total hospital cost savings 
were greater when enoxaparin was used instead of unfraction-
ated heparin in patients with more severe stroke (cost-saving 
$287 if NIHSS score $ 14 versus $71 if NIHSS score , 14). 
  Sensitivity analyses were performed where cost parameters 
were varied by ±5%, ±10%, ±15%, ±30%, and ±40%; 
  enoxaparin remained less costly than unfractionated heparin 
in all cases. In a multivariate analysis,   differences in enox-
aparin drug costs, hospital costs for deep vein thrombosis, 
and probability of deep vein thrombosis for patients on 
enoxaparin were the factors with the greatest effect on the 
overall cost. The only scenario where the higher drug cost 
of prophylaxis with enoxaparin was not completely offset 
by the reduction in events compared with unfractionated 
heparin, was a scenario which used a published ratio of 
asymptomatic deep vein thrombosis to symptomatic VTE to 
account for the fact that not all VTE events in the real-world 
present with symptoms prompting treatment and, therefore, 
costs. This scenario was limited by the fact that the ratio was 
derived from different patient populations receiving different 
anticoagulants than stroke patients.8
The Joint Commission and the National Quality Forum 
in the United States have recently introduced a set of quality 
assurance measures within the “National   Consensus Standards 
for the Prevention and Care of Venous   Thromboembolism” 
project,35 with the speciﬁc goal of improving inhospital VTE 
assessment, diagnosis, prophylaxis, and treatment. Three 
process measures focus on VTE prevention, ie, VTE-1 
assesses the proportion of patients who received any pro-
phylaxis, VTE-2 evaluates prophylaxis after admission to 
the intensive care unit, and VTE-6 assesses the incidence 
of potentially preventable hospital-acquired VTE. With 
national performance measures highlighting the need for 
hospitals to examine their VTE practices, the relative costs 
of different regimens are of particular importance to health 
care decision-makers. The use of clinically effective and 
cost-effective prophylaxis regimens should help to prevent 
VTE and its clinical and economic consequences, and ensure 
hospitals meet performance measures. In addition, the CMS 
has   recognized hospital-acquired VTE as a preventable 
condition.36 CMS have classiﬁed VTE after total knee or hip 
replacement as a preventable hospital-acquired condition and 
will not pay any incremental costs, leaving hospitals to bear 
the ﬁnancial burden. Whether this or other ﬁnancial-based 
incentives will be extended to include VTE after acute isch-
emic stroke remains to be seen.
Conclusion
VTE is a common complication after acute ischemic stroke.4 
Although none of the LMWHs is indicated for thrombo-
prophylaxis speciﬁcally in patients with acute ischemic 
stroke, guidelines from the American College of Chest 
Physicians recommend that patients with acute ischemic 
stroke and restricted mobility receive prophylactic low-dose 
subcutaneous unfractionated heparin or a LMWH, unless 
  contraindicated.5 Results from clinical studies suggest that 
enoxaparin is preferable to unfractionated heparin for VTE 
prophylaxis in patients with acute ischemic stroke and 
restricted mobility due to a better clinical beneﬁt-to-risk ratio, 
with the added convenience of once-daily administration.6 
In line with ﬁndings from modeling studies and real-world 
data in acutely ill medical patients, recent economic data 
indicate that the higher drug cost of enoxaparin is offset by 
the reduction in clinical events as compared with the use of 
unfractionated heparin for the prevention of VTE, particularly 
in patients with severe stroke.7 However, this cost-analysis 
in stroke patients is based on one open-label, randomized, 
controlled trial only. The data reviewed here suggest that 
preferential use of enoxaparin over unfractionated heparin 
may lead to reduced VTE rates and concomitant cost-savings 
in clinical practice. Furthermore, a once-daily injection has 
the advantage in clinical practice of simplifying treatment 
and improving compliance with both patients and physicians, 
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decreasing nursing time, and providing prophylaxis in an 
outpatient setting in addition to decreasing costs.37
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